Pharmacogenetics of controlled ovarian hyperstimulation.
Controlled ovarian hyperstimulation (COH) is a routine treatment employed in most assisted reproductive techniques (ARTs). The existence of genetic factors involved in COH has been suspected. The main challenge for clinicians involved in ART is COH cycle cancellation, which usually occurs due to two opposing situations. On the one hand, there is the presence of a poor response during COH treatment, and on the other there is the presentation of a side effect related to gonadotropin hypersensitivity (ovarian hyperstimulation syndrome [OHSS]). Evidence for an association between single nucleotide polymorphisms and COH outcome has been obtained during the last decade. The genetic dissection of both extreme phenotypes of COH will be the main objective of this review. The development of predictive panels useful for the clinical management of COH is currently underway, and will improve the clinical management of patients undergoing ART.
de Castro
Francisco
F
Hospital Universitario Príncipe de Asturias, Unidad de Reproducción Humana Asistida, Alcalá de Henares, Madrid, Spain.
Morón
Francisco J
FJ
Montoro
Luis
L
Real
Luis M
LM
Ruiz
Agustín
A
D002996:Clomiphene / Q000494:pharmacology; D004967:Estrogens / Q000819:agonists; D005260:Female; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors; D006801:Humans; D008596:Menotropins / Q000008:administration & dosage; D010053:Ovary / Q000187:drug effects / Q000502:physiology*; D010062:Ovulation Induction; D010597:Pharmacogenetics; D020641:Polymorphism, Single Nucleotide; D011247:Pregnancy; D011962:Receptors, FSH / Q000502:physiology
D004967:Estrogens; D011962:Receptors, FSH; D002996:Clomiphene; D007987:Gonadotropin-Releasing Hormone; D008596:Menotropins; D005640:Follicle Stimulating Hormone